AMLX (Amylyx Corp) Forward P/S Multiple
Amylyx Pharmaceuticals (AMLX) is restarting its innovation cycle, urgently developing new molecules following failures with its primary drug. The future P/S multiple visualizes market expectations, while the value of -2318.10 shows the current magnitude of the metric. The company's revenues are based on insurance company payments for ALS treatment. The absence of its own manufacturing plants forces the company to rely on external contract manufacturers.
Summary analytical data breakdowns for Amylyx Corp (AMLX)
- market price and analyst price targets:
- business market valuation indicators:
- issuer book value statistics:
- debt and solvency information:
Debt to Equity Amylyx Pharmaceuticals|AMLX - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Amylyx Pharmaceuticals|AMLX - Company Aggregate Debts|Debts to Book Capitalization Amylyx Corp|AMLX - Company Long-Term Liabilities|Company Short-Term Debts Amylyx Pharmaceuticals|Quick Liquidity Indicator amylyx.com
- financial results and valuation multiples details:
AMLX - Net Profit|Future Profit Amylyx Pharmaceuticals|AMLX - Market Price to Net Income Ratio|Forward P/E Multiple Amylyx|AMLX - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple Amylyx Corp|AMLX - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Amylyx Pharmaceuticals|AMLX - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months amylyx.com|AMLX - Earnings per share growth in current year|Net earnings per share growth forecast for next year Amylyx Pharmaceuticals
- total revenue and sales volume data:
Fundamental company analysis:Amylyx Pharmaceuticals, Inc. AMLX
For Amylyx Pharmaceuticals (AMLX), the projected revenue multiple reflects market confidence in drug commercialization amid R&D personnel losses. The projected P/S ratio correlates current market value with expected sales, excluding quarterly reporting delays. A decline in this indicator may signal undervaluation or rising risks due to weakened scientific potential. Investors should evaluate the trend line as a marker of business resilience.
Competitors of Amylyx Pharmaceuticals (AMLX)
Price-to-Projected Revenue Ratio Biogen BIIB|NBIX (Neurocrine) - Future Price to Revenue|Regencell - Forward P/S Multiple|Forward Price to Sales AXSM (Axsome Corp)|ACAD: Forward P/S Multiple|xenon-pharma.com (XENE) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Viking Therapeutics, Inc.|SUPN: Forward Price to Sales|Price-to-Projected Revenue Ratio Catalyst Pharmaceuticals Inc (CPRX)|Forward Price-to-Revenue Multiple Denali Corp DNLI|Forward P/S Multiple HRMY (Harmony Biosciences)|Forward P/S Multiple biohavenpharma.com BHVN|Trevi Therapeutics, Inc. - Forward P/S Multiple|Praxis Precision Medicines Inc (PRAX) - Forward Price-to-Revenue Multiple|AVXL: Forward P/S Multiple|Market Cap to Future Revenue Ratio CeriBell EEG (CBLL)|Forward Price-to-Revenue Multiple PRTA|Forward P/S Multiple Alector Therapeutics|Forward Price-to-Revenue Multiple ANNX (Annexon)|Price to Expected Revenue Ratio OMER|Forward P/S Multiple NGNE (Neurogene Corp)|Market Cap to Expected Sales Ratio AC Immune Inc (ACIU)|Voyager Therapeutics - Forward P/S Multiple|neumoratx.com (NMRA) - Forward Price-to-Revenue Multiple|SCLX: Forward P/S Multiple|Tevogen Bio Holdings Inc. (TVGN) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Alpha Cognition Inc|Price-to-Projected Revenue Ratio CGTX|Price-to-Projected Revenue Ratio Inhibikase Therapeutics (IKT)|Market Cap to Expected Sales Ratio cassavasciences.com|Forward P/S Multiple ASRT (Assertio)|Forward P/S Multiple Coya Therapeutics Inc COYA|VTGN - Price-to-Projected Revenue Ratio|Ovid Therapeutics Inc. (OVID) - Forward Price-to-Revenue Multiple|Acumen Pharmaceuticals (ABOS) - Price-to-Projected Revenue Ratio|CRVO (cervomed.com) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple ATHE|Market Cap to Projected Revenue CLNN (Clene Nanomedicine)|Price-to-Projected Revenue Ratio PepGen Inc. (PEPG)|Jupiter Neurosciences, Inc. - Market Cap to Projected Revenue|Forward P/S Multiple RLMD (Relmada Therapeutics)|annovisbio.com (ANVS) - Market Cap to Future Revenue Ratio|GRCE: Forward Price-to-Revenue Multiple|AIFF - Forward P/S Multiple|anewmeds.com (KLTO) - Price-to-Projected Revenue Ratio|NeuroSense Therapeutics Ltd. - Forward Price to Sales|Price-to-Projected Revenue Ratio Reviva Pharmaceuticals|Market Cap to Future Revenue Ratio MetaVia, Inc. MTVA|Forward P/S Multiple NRXS|Forward P/S Multiple heliusmedical.com (HSDT)|Price-to-Projected Revenue Ratio Passage Bio PASG|NEUP - Forward Price-to-Revenue Multiple|NERV: Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio athira.com|Addex Therapeutics Ltd (ADXN) - Price-to-Projected Revenue Ratio|ALZN (Alzamend Neuro) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple CYCN|Market Cap to Future Revenue Ratio Protagenic PTIX|Forward Price-to-Revenue Multiple KTTA (Pasithea Therapeutics)|cortigent.com - Market Cap to Projected Revenue|Avenue Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Forward Price to Sales BCLI|CARA - Price-to-Projected Revenue Ratio|Future Price to Revenue CHRO|ELYM: Forward P/S Multiple|Intra-Cellular Therapies, Inc. - Forward Price to Sales|LBPH (Longboard Pharmaceuticals, Inc.) - Forward P/S Multiple|Forward P/S Multiple Marinus Pharmaceuticals Inc|Price-to-Projected Revenue Ratio NKGen (NKGN)|NRBO (NeuroBo Pharma) - Forward Price to Sales|Price-to-Projected Revenue Ratio Sage Therapeutics, Inc. SAGE|SNPX - Forward Price-to-Revenue Multiple|Trevena - Forward P/S Multiple|VIGL - Forward P/S Multiple|WENA: Forward P/S Multiple|Forward Price-to-Revenue Multiple Cerevel Corp
